Literature DB >> 6218870

Mitogen responsiveness and inhibitory activity of mesenteric lymph node cells. Conditioned medium containing T cell growth factor reverses suppressor function.

B M Vose, R Ferguson, M Moore.   

Abstract

Blood-, lymph node-, and tumour-infiltrating lymphocytes (PBL, LNC, and TIL, respectively) from patients with colonic neoplasms were tested for responsiveness to phytohaemagglutinin (PHA). All populations responded, with LNC and PBL showing comparable reactivities while TIL were less reactive as assessed by incorporation of 3H-thymidine. Increased mitogen responsiveness was observed for T cells enriched by SRBC rosette formation or passage through nylon columns. Mitomycin C-treated LNC and TIL inhibited PHA induced 3H-thymidine incorporation of admixed autologous PBL, suggesting the presence of suppressor cells. Suppressor activity resided primarily in the SRBC rosetting population and was dose-dependent, with increasing numbers of LNC giving greater diminution of PHA response. Suppression by LNC was apparent only when they were added to PBL responders within 6 h of the initiation of stimulation assays, in common with the effects of Concanavalin A (Con A)-induced suppressors on PBL phytomitogen responsiveness. Con A-induced and LNC-suppressor activity could be reversed by addition of lymphocyte-conditioned medium (CM) containing T cell growth factor (TCGF; interleukin IL-2). These data provide further evidence that the suppressor phenomena observed in this system are a function of activated T cells present both in drainage lymph nodes and at the tumour site.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218870     DOI: 10.1007/bf00205309

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

1.  The suppressive effect of a supernate from concanavalin A-activated human lymphocytes: effects of concanavalin A-activated lymphocytes and their supernates on cytotoxic and mixed lymphocyte reactions.

Authors:  D B Kaufman; C Carnaud; J L Stach; J F Bach
Journal:  Cell Immunol       Date:  1979-09-15       Impact factor: 4.868

2.  Immunosuppression in man: suppression by macrophages can be mediated by interactions with regulatory T cells.

Authors:  J D Stobo
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

3.  Human suppressor T cells induced by concanavalin A: suppressor T cells belong to distinctive T cell subclasses.

Authors:  T Sakane; I Green
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

4.  Characterization of suppressor lymphocytes generated in vitro.

Authors:  R M Ferguson; S M Anderson; R L Simmons
Journal:  Transplantation       Date:  1978-11       Impact factor: 4.939

5.  Reduced lymphocyte transformation in breast cancer.

Authors:  M G Whittaker; K Rees; C G Clark
Journal:  Lancet       Date:  1971-05-01       Impact factor: 79.321

6.  Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: the role of suppressor cells.

Authors:  M Zembala; B Mytar; T Popiela; G L Asherson
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

7.  Prostaglandin-producing suppressor cells in Hodgkin's disease.

Authors:  J S Goodwin; R P Messner; A D Bankhurst; G T Peake; J H Saiki; R C Williams
Journal:  N Engl J Med       Date:  1977-11-03       Impact factor: 91.245

8.  Ligand-activated T cell growth factor-induced proliferation: absorption of T cell growth factor by activated T cells.

Authors:  G D Bonnard; K Yasaka; D Jacobson
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

9.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

10.  In vitro studies of the rabbit immune system. V. Suppressor T cells activated by concanavalin A block the proliferation, not the induction of antierythrocyte plaque-forming cells.

Authors:  D Redelman; C B Scott; H W Sheppard; S Sell
Journal:  J Exp Med       Date:  1976-04-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Lymphocyte proliferation, lymphokine production, and lymphocyte receptors in ageing and various clinical conditions.

Authors:  A L de Weck; F Kristensen; F Joncourt; F Bettens; C Walker; Y Wang
Journal:  Springer Semin Immunopathol       Date:  1984

2.  Tumour-associated proliferative responses in vitro of regional lymph nodes draining solid cancers in man.

Authors:  T Mainou-Fowler; O Eremin
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Histologic and immunohistochemical characterization of tumor and inflammatory infiltrates in oral squamous cell carcinomas treated with local multikine immunotherapy: the macrophage at the front line.

Authors:  Meora Feinmesser; Elimelech Okon; Ariel Schwartz; Ella Kaganovsky; Britta Hardy; Elena Aminov; Ben Nageris; Jaqueline Sulkes; Raphael Feinmesser
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-10-24       Impact factor: 2.503

4.  Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

Authors:  E Halapi; Y Yamamoto; C Juhlin; M Jeddi-Tehrani; J Grunewald; R Andersson; C Hising; G Masucci; H Mellstedt; R Kiessling
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

5.  In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.

Authors:  J S Economou; A S Belldegrun; J Glaspy; E M Toloza; R Figlin; J Hobbs; N Meldon; R Kaboo; C L Tso; A Miller; R Lau; W McBride; R C Moen
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

6.  Different pattern of T cell receptor delta gene rearrangement in tumour-infiltrating lymphocytes and peripheral blood in patients with solid tumours.

Authors:  D Kowalczyk; W Skorupski; M Drews; J Nowak
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.